Zepbound - Tirzepatide for obesity approval

from Docs Who Lift · host Docs Who Lift

Drs. Karl and Spencer discuss how tirzepatide is now approved for obesity. Learn: When will it be available How much will is cost Any differences compared to Mounjaro Surmount 3 trial Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Nov 10, 2023

Embed this episode

Attribution link and audio player

What this episode covers

Drs. Karl and Spencer discuss how tirzepatide is now approved for obesity. Learn: When will it be available How much will is cost Any differences compared to Mounjaro Surmount 3 trial

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Zepbound - Tirzepatide for obesity approval

0:00 23:05

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Docs Who Lift?

This episode is 23 minutes long.

When was this Docs Who Lift episode published?

This episode was published on November 10, 2023.

Can I download this Docs Who Lift episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!